4D Molecular Therapeutics vs Century Therapeutics
FDMT and IPSC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How FDMT and IPSC compare
4D Molecular Therapeutics is the larger company, worth 3.0 times as much as Century Therapeutics ($938M against $315M).
Century Therapeutics scores higher on the StockData Score (8 against 7 for 4D Molecular Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | FDMT | IPSC |
|---|---|---|
| Size and price | ||
| Market cap | $938M | $315M |
| Share price | $12.99 | $1.74 |
| Change, 1 year | 27.7% | 217% |
| Change, 5 years | −43.7% | −91.6% |
| Beta (5Y) | 1.35 | 1.37 |
| Employees | 196 | 78 |
| StockData Score | ||
| Total score | 7 | 8 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 2 (better) | 1 |
| Performance score | 2 (better) | 1 |
| Health score | 3 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 10.2× | – |
| P/B | 2.3× | 1.5× (better) |
| FCF yield | – | −27.0% |
| Fair value | $12.76 | – |
| Margin of safety | −1.8% | – |
| Growth | ||
| Revenue growth (TTM) | 278712% | – |
| Revenue growth, 5Y average | 44.3% | – |
| Profitability | ||
| Operating margin | −214% | – |
| Net margin | −195% | – |
| Return on equity | −43.3% (better) | −51.2% |
| Return on invested capital | −161% | −126% (better) |
| Financial health | ||
| Debt / equity | 0.05 (better) | 0.00 |
| Current ratio | 8.03 | 8.74 (better) |
| Altman Z-score | 3.87 (better) | −1.89 |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Buyback yield | – | −0.22% |
| Shareholder yield | 0.00% (better) | −0.22% |
| Ownership | ||
| Held by institutions | 80.5% | 87.3% |
| Held by insiders | 2.1% | 3.8% |
| Insider net buying, 12 months | −$5.3M | $10.6K (better) |
| Short interest, % of float | 15.4% | 18.4% |
Go deeper
- FDMT stock overview
- FDMT income statement
- FDMT valuation and score
- IPSC stock overview
- IPSC income statement
- IPSC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.